Molecular structure of Emricasan, CAS Number: 254750-02-2
Emricasan (CAS 254750-02-2)
Alternate Names:
IDN-6556; PF-03491390
CAS Number:
254750-02-2
Molecular Weight:
569.5
Molecular Formula:
C26H27F4N3O7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Emricasan (CAS 254750-02-2) References
- Current and future pharmacological therapies for NAFLD/NASH. | Sumida, Y. and Yoneda, M. 2018. J Gastroenterol. 53: 362-376. PMID: 29247356
- Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. | Eguchi, A., et al. 2018. J Mol Med (Berl). 96: 575-583. PMID: 29728708
- Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo. | Frenette, CT., et al. 2019. Clin Gastroenterol Hepatol. 17: 774-783.e4. PMID: 29913280
- Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. | Garcia-Tsao, G., et al. 2019. Hepatology. 69: 717-728. PMID: 30063802
- Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. | Gracia-Sancho, J., et al. 2019. Hepatol Commun. 3: 987-1000. PMID: 31304452
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. | Harrison, SA., et al. 2020. J Hepatol. 72: 816-827. PMID: 31887369
- Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. | Frenette, C., et al. 2021. J Hepatol. 74: 274-282. PMID: 33038432
- Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis. | Mu, LY., et al. 2021. Clinics (Sao Paulo). 76: e2409. PMID: 34133478
- The impact of emricasan on chronic liver diseases: current data. | Lekakis, V. and Cholongitas, E. 2022. Clin J Gastroenterol. 15: 271-285. PMID: 35000120
- Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials. | Jie, Y., et al. 2023. Afr Health Sci. 23: 402-408. PMID: 38223578
Inhibitor of:
BID, C9orf82, caspase-1, caspase-13, caspase-5, caspase-9, CDSN, CHCHD2, GP2, ICE p20, ICE-LAP6, ICH-1S, MACHβ1, p20-ARC, Pdcd-7, Programmed cell death (PDCD), RKIP, and TRUNDD.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Emricasan, 5 mg | sc-507387 | 5 mg | $90.00 |